PerkinElmer Board Declares Quarterly Dividend

1/26/23 4:15:00 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $PKI alert in real time by email

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 12, 2023 to all shareholders of record at the close of business on April 21, 2023.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005743/en/

Get the next $PKI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PKI

Date	Price Target	Rating	Analyst
12/19/2022	$170.00	Sector Weight → Overweight	KeyBanc Capital Markets
12/12/2022	$135.00 → $170.00	Neutral → Buy	Citigroup
12/6/2022	$192.00 → $164.00	Market Perform → Outperform	Cowen
11/28/2022	$130.00 → $145.00	Underweight → Equal Weight	Barclays
8/25/2022	$175.00	Neutral	Credit Suisse
8/18/2022	$190.00 → $170.00	Buy → Hold	Stifel
8/2/2022	$178.00	Buy → Neutral	BofA Securities
7/20/2022	$160.00	Buy	UBS

More analyst ratings

$PKI
Leadership Updates

Live Leadership Updates

James Mock Joins Moderna as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a
8/17/22 8:00:00 AM ET
$MRNA
$PKI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
PerkinElmer Announces Finance Leadership Transition
Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey
8/17/22 8:00:00 AM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021
Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a
4/13/21 4:15:00 PM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials

Revvity Announces Financial Results for the First Quarter of 2023
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp
5/11/23 6:00:00 AM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev
5/9/23 8:00:00 AM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon
4/25/23 4:05:00 PM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials

Revvity Announces Financial Results for the First Quarter of 2023
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp
5/11/23 6:00:00 AM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev
5/9/23 8:00:00 AM ET
$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
Ares Management Corporation Announces U.S. Direct Lending Origination Activity for the First Quarter and Last Twelve Months 2023
Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun
4/28/23 6:30:00 AM ET
$ARES
$PKI
Investment Managers
Finance
Biotechnology: Laboratory Analytical Instruments
Industrials

PerkinElmer Board Declares Quarterly Dividend

Chat with this insight

Recent Analyst Ratings for $PKI

$PKI Leadership Updates

Live Leadership Updates

James Mock Joins Moderna as Chief Financial Officer

PerkinElmer Announces Finance Leadership Transition

PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

$PKI Financials

Live finance-specific insights

Revvity Announces Financial Results for the First Quarter of 2023

Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure